July 23, 2019 09:35 AM EDTUpdated 01:18 PM

Myovant's uterine fibroid drug looks competitive in PhIII — but can they vanquish mighty AbbVie?

John Carroll

Editor & Founder

Vivek Ramaswamy’s Myovant $MYOV has closely matched its positive first round of Phase III data for their uterine fibroid drug relugolix, setting up a head …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Myovant's uterine fibroid drug looks competitive in PhIII — but can they vanquish mighty AbbVie?

John Carroll

Editor & Founder

Sign up to read this article for free.

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Updated: Novo’s 23% weight loss with CagriSema falls short of high expectations, new trial planned

FDA approves Humacyte’s lab-grown blood vessels in milestone for regenerative medicine

Califf, on his way out at FDA, predicts agency tug-of-war between Ramaswamy and RFK Jr.

Exclusive: Florida cancer biotech raises $100M Series A

Sofinnova outlines $550M fund after IPOs and M&A deals

My­ovan­t's uter­ine fi­broid drug looks com­pet­i­tive in PhI­II — but can they van­quish mighty Ab­b­Vie?

John Carroll

Editor & Founder

Sign up to read this article for free.

more like this

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Myovant's uterine fibroid drug looks competitive in PhIII — but can they vanquish mighty AbbVie?

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Updated: Novo’s 23% weight loss with CagriSema falls short of high expectations, new trial planned

FDA approves Humacyte’s lab-grown blood vessels in milestone for regenerative medicine

Califf, on his way out at FDA, predicts agency tug-of-war between Ramaswamy and RFK Jr.

Exclusive: Florida cancer biotech raises $100M Series A

Sofinnova outlines $550M fund after IPOs and M&A deals